[The antibacterial activity of new cephem antibiotics against clinical isolates. A comparison of the antibacterial activity of cefotaxime with 6 other antibiotics]
- PMID: 6304368
[The antibacterial activity of new cephem antibiotics against clinical isolates. A comparison of the antibacterial activity of cefotaxime with 6 other antibiotics]
Abstract
During the period from May through July 1981, a comparative study was carried out on the antibacterial activities of cefotaxime (CTX) and ceftizoxime (CZX), cefoperazone (CPZ), latamoxef (LMOX), cefotiam (CTM), cefmetazole (CMZ) and cefazolin (CEZ). CTX and these other cephem antibiotics were tested against fresh clinical isolates which had been obtained from clinical materials by the laboratories of 14 participating medical institutions. 1. The clinical isolates were obtained from various clinical materials in the following decreasing order: urine, sputum and pus/discharge; 85.7% of the isolates came from these materials. 2. Concerning the sources of each species of clinical isolates, it was found that P. aeruginosa was isolated from the greatest number -9- of different clinical materials. This was followed by E. coli and E. cloacae, each isolated from 8 different clinical materials, and C. freundii and E. aerogenes, each found in 7 different clinical materials. 3. In relation to S. pyogenes, S. agalactiae and S. pneumoniae, CTX showed the best antibacterial activity; the second most potent antibiotic was CZX. CMZ and LMOX were found to show relatively high MIC values for those species. Against S. aureus, CEZ showed the best antibacterial activity, but 3 resistant strains had MICs of greater than 100 micrograms/ml. 4. With regard to Gram-negative bacteria, CTX and CZX showed the best antibacterial activities for all of the species, except for P. aeruginosa. These were followed, in order, by LMOX and CPZ. Compared with these 4 antibiotics, CTM, CMZ and CEZ were found to have inferior antibacterial activities against these bacteria. In relation to P. aeruginosa, the peak of the MIC distribution for CPZ was 6.25 micrograms/ml, and this was the best antibacterial activity detected with the various antibiotics tested. This was followed by CTX (25 micrograms/ml) LMOX (25 micrograms/ml) and CZX (50 micrograms/ml). CTM had an MIC of 100 micrograms/ml for 1 strain, and MICs of greater than 100 micrograms/ml for all of the other strains of P. aeruginosa, indicating them to be resistant to this antibiotic. All of the strains were resistant to CMZ and CEZ, showing MICs of greater than 100 micrograms/ml. 5. For each of the tested antibiotics, no correlation was found between the MIC and the serogroup for either P. aeruginosa or S. marcescens.
Similar articles
-
[Comparison of in vitro activity of first, second and third generation cephem antibiotics against various pathogens isolated from clinical materials in 1983].Jpn J Antibiot. 1984 Jun;37(6):1040-57. Jpn J Antibiot. 1984. PMID: 6387213 Japanese.
-
[Antibacterial activities of new cephems against clinically isolated organisms (author's transl)].Jpn J Antibiot. 1982 Apr;35(4):1009-21. Jpn J Antibiot. 1982. PMID: 6285019 Japanese.
-
[Comparison of sensitivity patterns of bacteria isolated from clinical materials to the 2d generation cephamycins and cephalosporins and clinical application of these antibiotics].Jpn J Antibiot. 1983 Jul;36(7):1621-37. Jpn J Antibiot. 1983. PMID: 6317908 Japanese.
-
Cefotaxime: a review of in vitro antimicrobial properties and spectrum of activity.Rev Infect Dis. 1982 Sep-Oct;4 Suppl:S300-15. doi: 10.1093/clinids/4.supplement_2.s300. Rev Infect Dis. 1982. PMID: 6294779 Review.
-
Third-generation and investigational cephalosporins: II. Microbiologic review and clinical summaries.Drug Intell Clin Pharm. 1983 Sep;17(9):615-22. doi: 10.1177/106002808301700901. Drug Intell Clin Pharm. 1983. PMID: 6311502 Review.
Cited by
-
Study on transfer of cefotaxime into bone tissue.Drugs. 1988;35 Suppl 2:88-92. doi: 10.2165/00003495-198800352-00019. Drugs. 1988. PMID: 3396494 No abstract available.
-
In vitro activity of cefotaxime against clinically significant pathogens.Drugs. 1988;35 Suppl 2:14-21. doi: 10.2165/00003495-198800352-00006. Drugs. 1988. PMID: 3260852